Page 11 - Delaware Medical Journal - October 2017
P. 11
CANCER CLINICAL TRIAL
PROTOCOL OF THE MONTH
EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Primary Objective:
To evaluate whether adjuvant therapy with nivolumab will result in improved overall survival (OS) and/or disease-free survival (DFS)
Secondary Objectives:
Eligibility Criteria:
Registration: CYCLE = 2 Weeks
ARM A:
ARMB: ObservationArm:
The Delaware Cancer Treatment Program (DCTP)
For information regarding clinical trials
or if you would like to have the list of open protocols e-mailed to you, akee@christianacare.org.
Del Med J | October 2017 | Vol. 89 | No. 10 299
